Royal Bank of Canada Raises Accenture (NYSE:ACN) Price Target to $340.00

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Nathanaels Gray ,Jamese Bradner ,Richarda Young ,Piper Sandler ,Acadian Asset Management ,Analyst Recommendations For Syros Pharmaceuticals ,Syros Pharmaceuticals Price Performance ,Syros Pharmaceuticals ,Topco Ltd ,Syros Pharmaceuticals Company Profile ,Advisor Group ,Nasdaq ,Syros Pharmaceuticals Inc ,Hermes Inc ,Renaissance Technologies ,Institutional Investors Weigh In On Syros Pharmaceuticals ,News Ratings For Syros Pharmaceuticals Daily ,Get Rating ,Marketbeat Ratings ,Asset Management ,Syros Pharmaceuticals Daily ,Nasdaq Syrs ,Syrs ,Medical ,Ratings ,Consensus ,